Literature DB >> 12271293

Quantifying the harmful effect of psoriasis on health-related quality of life.

Stefan C Weiss1, Alexa B Kimball, David J Liewehr, Andrew Blauvelt, Maria L Turner, Ezekiel J Emanuel.   

Abstract

BACKGROUND: Psoriasis affects 7 million people in the United States, causing substantial cost, social stigma, and disability.
OBJECTIVE: The purpose of this study was to evaluate the health effects of skin disease by comparing psoriasis to other primary medical disorders using 3 different scales of health-related quality of life.
METHODS: A self-administered questionnaire consisting of 3 health-related quality of life measures was given sequentially to 35 eligible patients with psoriasis presenting to the Dermatology Branch of the National Cancer Institute (NCI) for an investigational therapeutic protocol.
RESULTS: All patients (100%) agreed to participate. The median Psoriasis Area and Severity Index (PASI) score was 13.0. Overall, 82.9% at least often felt the need to hide their psoriasis, and 74.3% claimed their self-confidence was at least often affected by their psoriasis. The median EQ-5D health state utility score was 13.0% less than healthy individuals (P <.001). On the SF-36, the mean general health score was 13.2% less (P =.005) and the median social functioning score 18.7% less (P =.005) than that of patients with no chronic conditions.
CONCLUSION: Individuals with psoriasis are significantly affected in their health state utility, perception of general health, and social functioning when compared with individuals without chronic disease and those with certain primary medical conditions.

Entities:  

Mesh:

Year:  2002        PMID: 12271293     DOI: 10.1067/mjd.2002.122755

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  45 in total

1.  [Health economics studies in dermatology].

Authors:  C Rogalski; J Simon; U Paasch
Journal:  Hautarzt       Date:  2006-04       Impact factor: 0.751

2.  Physical and mental impact of psoriasis severity as measured by the compact Short Form-12 Health Survey (SF-12) quality of life tool.

Authors:  Ivan Grozdev; Douglas Kast; Lauren Cao; Diana Carlson; Prasad Pujari; Brian Schmotzer; Denise Babineau; Elizabeth Kern; Thomas McCormick; Kevin D Cooper; Neil J Korman
Journal:  J Invest Dermatol       Date:  2011-12-29       Impact factor: 8.551

3.  Amphiregulin and epidermal hyperplasia: amphiregulin is required to maintain the psoriatic phenotype of human skin grafts on severe combined immunodeficient mice.

Authors:  Narasimharao Bhagavathula; Kamalakar C Nerusu; Gary J Fisher; Gao Liu; Archana B Thakur; Lorraine Gemmell; Shankar Kumar; Zenghai H Xu; Paul Hinton; Naoya Tsurushita; Nicholas F Landolfi; John J Voorhees; James Varani
Journal:  Am J Pathol       Date:  2005-04       Impact factor: 4.307

4.  Infliximab improves health related quality of life and physical function in patients with psoriatic arthritis.

Authors:  A Kavanaugh; C Antoni; G G Krueger; S Yan; M Bala; L T Dooley; A Beutler; C Guzzo; D Gladman
Journal:  Ann Rheum Dis       Date:  2005-08-11       Impact factor: 19.103

Review 5.  Pain Management in Painful Psoriasis and Psoriatic Arthropathy: Challenging and Intricately Intertwined Issues Involving Several Systems.

Authors:  Vijay Kodumudi; Kanishka Rajput
Journal:  Curr Pain Headache Rep       Date:  2021-04-06

6.  Prevalence of psoriasis among adults in the U.S.: 2003-2006 and 2009-2010 National Health and Nutrition Examination Surveys.

Authors:  Charles G Helmick; Hyewon Lee-Han; Shawn C Hirsch; Tiffany L Baird; Christopher L Bartlett
Journal:  Am J Prev Med       Date:  2014-04-18       Impact factor: 5.043

7.  Palmoplantar psoriasis is associated with greater impairment of health-related quality of life compared with moderate to severe plaque psoriasis.

Authors:  Jina Chung; Kristina Callis Duffin; Junko Takeshita; Daniel B Shin; Gerald G Krueger; Andrew D Robertson; Andrea B Troxel; Abby S Van Voorhees; Emily Edson-Heredia; Joel M Gelfand
Journal:  J Am Acad Dermatol       Date:  2014-06-02       Impact factor: 11.527

Review 8.  Consumer empowerment in dermatology.

Authors:  Heather E Hoch; Kristine L Busse; Robert P Dellavalle
Journal:  Dermatol Clin       Date:  2009-04       Impact factor: 3.478

Review 9.  A review of health utilities across conditions common in paediatric and adult populations.

Authors:  Jean-Eric Tarride; Natasha Burke; Matthias Bischof; Robert B Hopkins; Linda Goeree; Kaitryn Campbell; Feng Xie; Daria O'Reilly; Ron Goeree
Journal:  Health Qual Life Outcomes       Date:  2010-01-27       Impact factor: 3.186

10.  Adalimumab improves health-related quality of life in patients with moderate to severe plaque psoriasis compared with the United States general population norms: results from a randomized, controlled Phase III study.

Authors:  Dennis A Revicki; Alan Menter; Steven Feldman; Miriam Kimel; Neesha Harnam; Mary K Willian
Journal:  Health Qual Life Outcomes       Date:  2008-10-02       Impact factor: 3.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.